Cyclooxygenase-2 expression in gastrointestinal stromal tumours.
BACKGROUND
While it is well known that cyclooxygenase-2 (COX-2) expression is increased in colorectal adenoma and carcinoma, there is only limited information on its status in stromal tumours.


METHODS
Immunohistochemical COX-2 staining was performed on a total of 42 confirmed gastrointestinal stromal tumours (GISTs) in the Pathology Department of Gaziantep University and the findings were compared with various other parameters.


RESULTS
We found a statistically significant correlation between the tumor mitosis and COX-2 expression in GISTs. However, there was no relationship between COX-2 expression and death rate, presence of metastasis, tumour size, risk staging, usage of tyrosine kinase inhibitors, and complete resection rate.


CONCLUSIONS
In the light of these findings, the usage of COX-2 inhibitors with or without tyrosine kinase inhibitors in GIST patients may be helpful in the adjuvant setting to prevent or delay recurrence. Moreover, we need more studies to define the status of COX-2 inhibitors in GISTs.
Department of Medical Oncology, Medical Faculty, Gaziantep Oncology Hospital, Gaziantep University, Gaziantep, Turkey.
Alper
A
Sevinc
Celalettin
C
Camci
Ibrahim
I
Sari
Mehmet Emin
ME
Kalender
Ozlem
O
Er
Isin
I
Soyuer
Mustafa
M
Dikilitas
Ugur
U
Yilmaz
Ozgur
O
Sagol
Ahmet
A
Alacacioglu
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D016009:Chi-Square Distribution; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000378:metabolism* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D006801:Humans; D000068877:Imatinib Mesylate; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D008938:Mitosis; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012189:Retrospective Studies; D000077210:Sunitinib; D015996:Survival Rate; D047368:Tumor Burden
D000970:Antineoplastic Agents; D001549:Benzamides; D052246:Cyclooxygenase 2 Inhibitors; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D051546:Cyclooxygenase 2; D011505:Protein-Tyrosine Kinases; D000077210:Sunitinib